Idiopathic Pulmonary Fibrosis clinical trials at UCSF

5 in progress, 2 open to eligible people

Showing trials for

  • DWN12088 in Patients With IPF

    open to eligible people ages 40 years and up

    This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

    San Francisco, California and other locations

  • Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    open to eligible people ages 40 years and up

    Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

    San Francisco, California and other locations

  • BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

    San Francisco, California and other locations

  • Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

    Sorry, accepting new patients by invitation only

    Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

    San Francisco, California and other locations

  • Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

    Sorry, in progress, not accepting new patients

    The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.

    San Francisco, California and other locations

Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include .

Last updated: